A Borderline QTc and a Frequent Exacerbator: Starting Azithromycin Anyway
A patient who fits the frequent-exacerbator profile chronic azithromycin was built for, complicated by a baseline QTc that sits close enough to the drug's own warning threshold to change how the decision gets made, not whether it does.
Frances O. worked the same postal route for twenty-six years before retiring, and still walks it some mornings out of habit more than exercise, though lately she has had to stop twice most days to catch her breath where she never used to stop at all. She quit smoking fifteen years ago after a pack-a-day habit going back to her twenties, and her COPD has been the frequent-exacerbator kind despite an optimized inhaled regimen — four exacerbations in the past year, two requiring a course of antibiotics on top of the usual steroid burst. Her pulmonologist raised chronic azithromycin at her last visit as the next real step, and she came back today having read enough about it to arrive with a specific question about her heart rather than her lungs.
Her routine ECG, done as part of the workup, shows a corrected QT interval of 452 milliseconds — not frankly abnormal, but close enough to the range where azithromycin’s own, real cardiovascular signal starts to matter. The evidence for the drug itself is genuine: COLUMBUS randomized patients who had been treated for three or more exacerbations in the prior year — her exact frequent-exacerbator phenotype, which she clears with four — to azithromycin 500 mg three times weekly for a year, and cut the exacerbation rate meaningfully; she is also precisely the nonsmoker GOLD’s own recommendation is written for. But the same literature is equally direct that azithromycin carries a small, real increase in cardiovascular death risk tied to QT prolongation, concentrated in patients who already have a borderline baseline or who are taking something else that prolongs it too — and nobody has yet checked her medication list against that second condition.
Weighing a real exacerbation problem against a number on an ECG
She is the patient GOLD wrote this recommendation for — a frequent exacerbator, four events in the past year despite optimized inhaled therapy, and a current nonsmoker, which is specifically the population the evidence and the guideline both target. COLUMBUS showed a real, meaningful exacerbation reduction with 500 mg three times weekly, in patients who like her had been treated for three or more exacerbations the year before. I would start it.
I am not arguing against starting it — I am arguing against starting it today, on this ECG, without a step in between. A QTc of 452 sits close enough to the range where azithromycin’s own real cardiovascular signal concentrates that I want a formal, repeat QTc measurement and a full reconciliation of her other medications for anything else that prolongs it before the first dose, not after we see what happens.
This is not a QTc that reflexively rules the drug out on its own — it is a QTc that changes how carefully we should check before we start it, which is a different, more answerable question.
I would name the resistance concern honestly and then set it in its right place. It is real at a population level — chronic macrolide exposure does carry a stewardship cost across a health system — but COLUMBUS’s own resistance substudy splits in a way worth stating in full: it found no increased acquisition of macrolide-resistance genes in the treated patients, but it did find the relative abundance of those genes rising significantly over the year compared with placebo. So the honest version is not that resistance failed to appear — it is that it appeared as enrichment rather than new acquisition, at a scale that operates across a health system rather than inside Frances’s own documented, guideline-matched indication. Once her cardiac workup clears her, I would not let a population-level consideration silently override a real individual benefit she is a genuine candidate for.
Agreed: proceed toward azithromycin, but sequence it — formal repeat QTc and a full medication reconciliation come first, with the prescription written contingent on both clearing.
Not agreed: the pulmonologist would have started azithromycin today with close monitoring rather than waiting on the formal workup, arguing her exacerbation risk is the more immediate concern; the cardiologist held firm that the QTc check should precede, not accompany, the first dose. The cardiologist's sequencing was adopted for this visit; not treated as settling the disagreement in general.